Johnson & Johnson's ($JNJ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are met--for a midstage blood-cancer treatment. Report
Formulation, process, and analytical development for ADCs is complex. Join our experts as we discuss ADC structure and function, the development process (including analytical methods, stability, and lyo cyle optimization) and parenteral product development. Register Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 90,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!